
Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Target
Recursion Pharmaceuticals (RXRX) Analyst Ratings
Bulls say
Recursion Pharmaceuticals is a leading company in the emerging field of machine learning and artificial intelligence applied to drug discovery, with major partnerships and significant opportunities in rare diseases. The company has a strong financial position with enough cash to fund operations into early 2028 and has several ongoing clinical programs that serve as a proof-of-concept for its platform. The upcoming feedback from the FDA on potential registrational study designs for REC-4881 in FAP is a major value driver for the company.
Bears say
Recursion Pharmaceuticals is a clinical-stage biotechnology company with promising technology and partnerships in the industry, including a recent milestone payment from Sanofi and a partnership with Roche. However, the company's clinical programs are still in early stages and there is no guarantee of success. Additionally, the company faces competition from other companies applying ML/AI to drug discovery. With ongoing clinical programs primarily serving to validate the platform's value, the company's collaborations with pharma partners will likely be the key driver of value.
This aggregate rating is based on analysts' research of Recursion Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Recursion Pharmaceuticals (RXRX) Analyst Forecast & Price Prediction
Start investing in Recursion Pharmaceuticals (RXRX)
Order type
Buy in
Order amount
Est. shares
0 shares